C12N 2770/24133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/24133 (Use of viral protein as therapeutic agent other than vaccine) appears on 5 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 8
- Assignees
- 5
- Inventors
- 18
- Latest grant
- 5 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Combination immunotherapies for treatment of cancer5 Aug 2025US 12,377,115 B2Primevax Immuno-Oncology, Inc.
- Materials and methods for inhibiting flavivirus infection18 Jul 2023US 11,702,453 B2The Regents of the University of Michigan
- Combination immunotherapies for treatment of cancer14 Jun 2022US 11,357,795 B2Primevax Immuno-Oncology, Inc.
- Combination immunotherapies for treatment of cancer9 Jun 2020US 10,675,304 B2Primevax Immuno-Oncology, Inc.
- DNA antibody constructs and method of using same2 Oct 2018US 10,087,240 B2Inovio Pharmaceuticals, Inc.
- Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof6 Mar 2025US 2025/0074950 A1Board of Regents, The University of Texas System
- Combination immunotherapies for treatment of cancer16 Feb 2023US 2023/0051860 A1Primevax Immuno-Oncology, Inc.
- Materials and Methods for Inhibiting Flavivirus Infection2 Sep 2021US 2021/0269490 A1The Regents of the University of Michigan
- Combination immunotherapies for treatment of cancer3 Sep 2020US 2020/0276235 A1Primevax Immuno-Oncology, Inc.
- Compositions and methods for cancer therapy with dengue virus and dendritic cells23 Apr 2020US 2020/0121745 A1Primevax Immuno-Oncology, Inc.
Most cited
By later US patents
- DNA antibody constructs and method of using same3US 10,087,240 B2Inovio Pharmaceuticals, Inc. · 2018
- Combination immunotherapies for treatment of cancer2US 10,675,304 B2Primevax Immuno-Oncology, Inc. · 2020
- Combination immunotherapies for treatment of cancer2US 11,357,795 B2Primevax Immuno-Oncology, Inc. · 2022